Martin Shkreli, the smirking Pharma CEO, has been replaced for now as the national symbol for outrage over Big Pharma’s price gouging. Enter, stage right: Heather Bresch, a 47-year-old executive−who also happens to be the daughter of a prominent U.S. senator. Bresch has become the villainess of the moment for her firm’s jacking up the cost of a drug that millions of Americans rely on to protect them from life-threatening allergy reactions.
Mylan is her company, and it is at the heart of the public furor over the adrenaline-dispensing device known as the EpiPen. (Adrenaline and Epi or epinephrine are the same drug.) The company’s name may sound as if it were taken from a Disney movie. But it is unclear whether there will be a happy ending to its current tale.
Will a sustained public outcry lead to real change in its business practices? Will this incident curb the ever-escalating efforts by Big Pharma to extract sky-high prices for products, some of which have been around so long the industry is far beyond recouping any research-and-development costs?